Ramucirumab
Ramucirumab
Immunoglobulin G1-kappa, anti-[Homo sapiens KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, VEGF-R2, FLK1, CD309)extracellular domain], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-446) [Homo sapiens VH (IGHV3-21*01(99.00%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) - IGHG1*03 (CH1 F5>L (125), hinge (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214'')-disulfide with kappa light chain (1''-214'') [Homo sapiens V-KAPPA (IGKV1-12*01 (85.30%) -IGKJ4*01E125>D (105)) [6.3.9] (1''-107'') -IGKC*01 (108''-214'')]; dimer (225-225'''':228-228'''')-bisdisulfide
Stoffgruppe
Antineoplastisches Mittel (VEGFR-Inhibitor)
Halbwertszeit
360 h
Präparate